COVID-19 Update

Due to the global COVID-19 pandemic and rapidly evolving public health organization guidance pertaining to its response, PAINWeek has made the decision to postpone the St. Louis PAINWeekEnd scheduled for April 18.

As you are undoubtedly aware, the Centers for Disease Control and Prevention (CDC) has recommended that in-person events comprising 50 or more attendees not be held for the next 8 weeks. Concurrently, various state and local authorities have begun directing the closure of bar, restaurant, and public service establishments in their jurisdictions. In view of the critical importance of these and other social distancing measures to attenuate the spread of infection and its impact on the healthcare system, we believe this postponement of our upcoming conferences is unavoidably necessary. A revised schedule for this conference will be developed and provided as soon as possible. Your registration will automatically transfer to the new date; however, you may request an immediate refund of your registration fee if you prefer.

If you made airline reservations, we recommend that you contact the airline to cancel. Most major carriers have added flexible change and cancellation policies. If you had plans to stay overnight, please contact the hotel directly to cancel your reservation.

The St. Louis Union Station will honor cancellations of or changes to, any existing reservation at no charge up to 24 hours before scheduled arrival. More details are available here.

We greatly regret the impact of this postponement on our attendees’ professional schedules and their interest in pain management education. As primary care practitioners, many of you are truly on the front lines of patient care in your communities, now more than ever in this uncertain time.

We are looking into adding more virtual and distance learning options. In the meantime, if you haven’t already done so, we recommend visiting the online education section of our website that includes articles, videos, interviews with thoughts leaders, and our PAINWeek Journal. We have also recently posted a webcourse entitled "Understanding and Addressing the Global Spread of the COVID-19 Infection: A Clinician's Guide" that is certified for 1-hour of CME/CE credit.

Please contact us with any questions or issues pertaining to your registration. Please accept our thanks for your understanding and support.

Saturday, April 18, 2020

  • REGISTRATION & EXHIBITS

    Coffee will be served.

  • Nonopioid Analgesics, Adjuvants, and Antidepressants

    Nonopioid analgesics are considered first-line therapy for most chronic pain syndromes. A strong recall of these agents’ safety and efficacy profiles is paramount for today’s pain practitioner. This course will provide an in-depth look at each of the agents within these drug classes, their potential role in pain management, and available data supporting their use. Additionally, clinically relevant monitoring will be discussed.

    • UAN: 0530-0000-20-030-L01-P
    • AANP Rx Hours: 1.00
  • PRODUCT, DISEASE AWARENESS, MEDICAL INFORMATION PROGRAM*

    Breakfast will be served.

    *This session is not certified for credit.

  • BREAK & EXHIBITS

  • Episodic vs Chronic Migraine: An Update on Novel and Emerging Therapeutic Options

    Why yet another lecture on migraine headaches, you ask? Migraine is the third most common disease in the world (behind dental caries and tension-type headache) with an estimated global prevalence of approximately 15% (that's around 1 in 7 people). Migraine is more prevalent than diabetes, epilepsy, and asthma combined. There continues to be a lack of education on primary headache disorders in clinical training and an underappreciation for the importance of aggressive treatment. This lecture will focus on distinguishing between episodic and chronic migraine, providing the audience with updates on diagnostic guidelines and the latest in current and emerging therapies.

    • UAN: 0530-0000-20-037-L01-P
    • AANP Rx Hours: 0.10
  • Regional Pain Syndromes: Neck and Back

    Every year, thousands of patients go see their primary care practitioner for the treatment of regional pain syndromes. This lecture focuses on regional pain syndromes including acute low back pain, chronic low back pain, cervicobrachial syndrome, cervical dystonia, lumbosacral/ cervical radiculopathy, spinal stenosis, and disk herniation. We will discuss symptoms, the physical exam, diagnostic testing, and pharmacologic/nonpharmacologic treatment options.

    • UAN: 0530-0000-20-040-L01-P
    • AANP Rx Hours: 0.00
  • FACULTY Q&A

  • BREAK & EXHIBITS

  • PRODUCT, DISEASE AWARENESS, MEDICAL INFORMATION PROGRAM*

    Lunch will be served.

    Sponsored by AstraZeneca-Daiichi Sankyo, Inc.

    *This session is not certified for credit.

  • Medicinal Cannabis: What You & Your Patients Need to Know

    With 47 states having passed legislation for the use of medicinal cannabis in some form or another, and the growing number of states passing legislation allowing for the use of recreational cannabis by their residents, the country is awash with green. Does cannabis have true utility as a medicine? What about addiction, psychosis, drug interactions, and driving under the influence? These and many other questions will be answered and discussed in this updated lecture.

    • UAN: 0530-0000-20-038-L01-P
    • AANP Rx Hours: Coming soon.
  • BREAK & EXHIBITS

  • PRODUCT, DISEASE AWARENESS, MEDICAL INFORMATION PROGRAM*

    Refreshments will be served.

    *This session is not certified for credit.

  • What's All the "GABA" About? Pregabalin and Gabapentin Abuse

    The gabapentinoids are a popular class of medications among prescribers for use in chronic pain and various other neurological conditions. In fact, prescription rates for both gabapentin and pregabalin have increased in the United States and other countries in recent years. However, these medications have a street value to a newer niche of users, including patients taking them at megadoses to enhance the effects of other psychotropic drugs, and other patients taking them to manage or mitigate opioid withdrawal symptoms and possibly even opioid cravings. While pregabalin is already classified as a controlled substance, gabapentin does not yet carry this classification. In response to rising abuse, various states and regulatory bodies are considering changes to enhance patient safety and protect the provider’s license. Learn what changes you should make to your practice, if any, in light of the growing abuse of gabapentinoids and how to identify patients potentially abusing them.

    • UAN: 0530-0000-20-036-L01-P
    • AANP Rx Hours: 0.00
  • Regional Pain Syndromes: Hip and Knee

    Every year, thousands of patients go see their primary care practitioner for the treatment of regional pain syndromes. This lecture focuses on regional pain syndromes including meralgia paresthetica, trochanteric bursitis, Baker’s cyst, meniscal injuries, cruciate ligament injuries, osteoarthritis of hip and knee, sacroiliac dysfunction, and piriformis syndrome. We will discuss symptoms, the physical exam, diagnostic testing, and pharmacologic/nonpharmacologic treatment options.

    • UAN: 0530-0000-20-039-L01-P
    • AANP Rx Hours: 0.00